Calamos Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 47 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,879,306
-34.3%
4,580,000
-35.3%
0.02%
-31.0%
Q2 2023$5,900,417
-3.5%
7,079,000
-1.8%
0.03%
-3.3%
Q1 2023$6,116,820
+5.8%
7,210,000
+21.6%
0.03%
+11.1%
Q4 2022$5,780,861
-71.4%
5,930,000
-75.1%
0.03%
-71.0%
Q3 2022$20,236,000
-47.5%
23,808,000
-45.4%
0.09%
-44.0%
Q2 2022$38,575,000
+0.4%
43,634,000
+0.0%
0.17%
+15.3%
Q1 2022$38,410,00043,624,0000.14%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Wellesley Asset Management 71,432$63,617,0004.32%
Western Asset Management Company, LLC 15,600,000$13,690,0004.04%
CAMDEN ASSET MANAGEMENT L P /CA 70,849,000$61,727,0001.84%
ZAZOVE ASSOCIATES LLC 16,992,000$14,985,0001.32%
Penn Mutual Asset Management, LLC 1,305,000$1,137,0001.32%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 64,750,000$56,413,0000.72%
CQS (US), LLC 10,000,000$8,777,0000.61%
ADVENT CAPITAL MANAGEMENT /DE/ 28,859,000$25,319,0000.40%
Context Capital Management, LLC 4,122$3,632,0000.24%
Hudson Bay Capital Management LP 19,500,000$17,152,0000.23%
View complete list of HALOZYME THERAPEUTICS INC shareholders